A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

  • End date
    Jan 1, 2027
  • participants needed
  • sponsor
    Nantes University Hospital
Updated on 22 December 2021


This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse .

The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria.

Following the screening period, patients will be enrolled and treated then, they will receive therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression.

Condition Multiple Myeloma at First Relapse
Treatment Ixazomib, Dexamethasone Oral, Iberdomide
Clinical Study IdentifierNCT04998786
SponsorNantes University Hospital
Last Modified on22 December 2021


Yes No Not Sure

Inclusion Criteria

Age > 70 years
Eastern Collaborative Oncology Group (ECOG) performance score of ≤2
Life expectancy > 6 months
Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care
Symptomatic multiple myeloma (MM) at first relapse, as defined below
Symptomatic multiple myeloma according to international criteria.(Rajkumar et al, 2014)
Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy
Subject must have received one prior line of therapy for at least 3 cycles
Subject has measurable disease at Screening, defined at least one of the following
Serum M-protein ≥ 0.5 gram (g)/deciliter (dL), OR
Urine M-protein ≥ 200 mg in 24 hours, OR
Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal
Subjects must meet the following laboratory parameters, per laboratory reference range
(performed at most 15 days before cycle 1 day 1)
Absolute neutrophil count (ANC) ≥ 1000/microliter (μL). Subjects may use growth factor support to achieve ANC eligibility criteria
Platelet count ≥ 75,000 /mm3 for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count ≥ 50,000/mm3 for subjects in whom > 50% of bone marrow nucleated cells are plasma cells. It is not permissible to transfuse subjects to achieve minimum platelet counts within 3 days before study
\--AST and ALT ≤ 3 × upper limit of normal (ULN)
Total bilirubin ≤ 1.5 × ULN. Subjects with documented Gilbert's syndrome may have bilirubin > 1.5 × ULN with the approval of the Primary Therapeutic Area Medical Director
Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/minute (min) (using Cockroft and Gault Formula)
Patient should comply with Celgene's pregnancy prevention plan for Iberdomide (please
see appendix 8 Iberdomide Pregnancy Prevention Plan for subjects in clinical
Female patients who
are postmenopausal for at least 24 months before the screnning visit, OR
are surgically sterile (have undergone a hysterectomy or bilateral oophorectomy)
Men even if surgically sterilized must agree to not father a child and agree to
practice complete abstinence or to use a condom during therapy and dose
interruptions and for 90 days after the last dose of study drug, even if they
have had a successful vasectomy, if their partner is of childbearing potential
or pregnant
Non-inclusion Criteria
Subject is refractory to bortezomib, defined as progression on or within 60 days of the last dose of bortezomib
Subject has had prior treatment with ixazomib, carfilzomib, pomalidomide or iberdomide
Subject has any of the following conditions
Non-secretory or oligo-secretory MM
Light chain Amyloidosis (AL Amyloidosis)
POEMS syndrome Waldenström macroglobulinemia
Known Human Immunodeficiency Viral (HIV) infection
Active hepatitis B or C infection based on blood screen tests
Significant cardiovascular or pericardial disease, including uncontrolled angina, hypertension, arrhythmia, recent myocardial infarction within 6 months, congestive, heart failure New York Heart Association (NYHA) Class ≥ 3
Major surgery within 4 weeks prior screening
Acute infections requiring parenteral therapy (antibiotic, antifungal or antiviral) within 14 days
≥ Grade 3 Peripheral neuropathy or grade 2 with pain
Uncontrolled diabetes or uncontrolled hypertension within 14 days
Any other medical condition that, in the opinion of the Investigator, would adversely affect the subject's participation in the study
Subject has a history of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry, with the following exceptions
Adequately treated in situ carcinoma of the cervix uteri or the breast
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment
Previous malignancy with no evidence of disease confined and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study
Known intolerance to steroid therapy
Serious medical or psychiatric illness likely to interfere with participation in study
Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs
Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note